News
This site is intended for health professionals only
Hospital Healthcare Europe
Register
Login
Linkedin
Facebook
Select Language
English
French
German
Italian
Spanish
News
In depth
Views
Conference reports
Reviews & Research
Practice
Health technology
Sustainability
Clinical
Cardiovascular
Dermatology
Emergency and critical care
Gastroenterology
Haematology
Immunology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Events
Upcoming events
On-demand learning
Clinical Excellence Catch-up
Partners
Register
Login
News
In depth
Views
Conference reports
Reviews & Research
Practice
Health technology
Sustainability
Clinical
Cardiovascular
Dermatology
Emergency and critical care
Gastroenterology
Haematology
Immunology
Medicines safety
Mental health
Neurology
Oncology
Paediatrics
Respiratory
Rheumatology
Events
Upcoming events
On-demand learning
Clinical Excellence Catch-up
Partners
Register
Login
Home
>
News
>
Asbjørn Mohr Drewes
Published on 10 August 2015
Share this story:
RELATED ARTICLES
Major clinical trial reforms take effect to accelerate new treatment access
Better monitoring of independent prescribing required to avoid missed opportunities, report says
Dupilumab shows sustained benefits for paediatric severe AD in first long-term analysis
‘New era’ for pharmacy as Royal College of Pharmacy officially launches
Consent capacity subject of new research programme to support equal trial access
Asbjørn Mohr Drewes
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe
Share this story:
RELATED ARTICLES
EMEA recommends on heparin-containing medicines
NPSA alert over opioid deaths
Warning over new NHS dress code
Patient safety and new technology challenges
Risk of severe COVID-19 infection among adults with prior exposure to children investigated
x
Search for: